Sutro Biopharma, Inc. Reports Departure of Director and Audit Committee Chair Shalini Sharp

Strategic Insights -

Sutro Biopharma, Inc. has reported the resignation of Shalini Sharp as a Class III director and Chair of the Audit Committee, effective immediately, on April 10, 2023. Sharp's resignation did not result from any disagreements with the company's management or the Board. In her place, Heidi Hunter, a Class I director and member of the Audit Committee, was appointed as the new Chair of the Audit Committee, effective April 13, 2023.

Key Takeaways:

  • Shalini Sharp resigned as a Class III director and Chair of the Audit Committee of Sutro Biopharma, Inc. on April 10, 2023.
  • Sharp's resignation was not due to any disagreements with the company's management or the Board.
  • Heidi Hunter was appointed as the new Chair of the Audit Committee, effective April 13, 2023.
  • Sharp's resignation does not appear to be related to any material disputes or concerns about the company's operations or financial reporting.
  • Sutro Biopharma, Inc. has reported that Hunter is a Class I director and member of the Audit Committee, indicating possible changes to the company's governance structure.
  • The company's financial reporting obligations and regulatory compliance appear unaffected by Sharp's resignation.

Statistics:

  • Date of Report: April 14, 2023 (per FORM 8-K filing)
  • Date of Resignation: April 10, 2023
  • Effective Date of Resignation: Immediately
  • Effective Date of New Audit Committee Chair Appointment: April 13, 2023
  • Company Name: Sutro Biopharma, Inc.
  • Exchange: Nasdaq Global Market
  • Stock Symbol: STRO

Sources:

  • United States Securities and Exchange Commission." FORM 8-K. April 14, 2023. U.S. Securities and Exchange Commission.